| pubmed-article:6308364 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:6308364 | lifeskim:mentions | umls-concept:C0034721 | lld:lifeskim |
| pubmed-article:6308364 | lifeskim:mentions | umls-concept:C0034693 | lld:lifeskim |
| pubmed-article:6308364 | lifeskim:mentions | umls-concept:C0027869 | lld:lifeskim |
| pubmed-article:6308364 | lifeskim:mentions | umls-concept:C0006050 | lld:lifeskim |
| pubmed-article:6308364 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:6308364 | lifeskim:mentions | umls-concept:C1707455 | lld:lifeskim |
| pubmed-article:6308364 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:6308364 | pubmed:dateCreated | 1983-9-9 | lld:pubmed |
| pubmed-article:6308364 | pubmed:abstractText | Local blockade of transmitter release was produced by s.c. injection of purified botulinum neurotoxin (NT) types A or E above the tibialis anterior muscle of adult male rats. Extensor digitorum longus nerve-muscle preparation was examined for toxin-induced alterations in single twitch and tetanic tension (in situ) or transmitter release (in vitro). For both single twitch and tetanic tension, muscles treated with type E NT recovered from an initial partial paralysis (induced with 56 mouse LD50) or full paralysis (induced with 565 mouse LD50) by 7 days after NT injection, while those treated with only 5 mouse LD50 of type A remained either fully or partially paralysed through 10 days. Also, miniature end-plate potential frequency and mean quantal content were reduced for a longer period of time and/or to a greater extent for muscles treated with type A NT than for those treated with type E. The present results are consistent with the observed higher specific toxicity (i.p. injections in mice) for type A NT than for type E, although these differences may be exaggerated after s.c. injections. The differences in the paralytic effect between types A and E may be determined by differences in amino acid sequence, which causes type E to dissociate more easily from its site of action and/or be detoxified more rapidly. The clinical implications of these findings are discussed. | lld:pubmed |
| pubmed-article:6308364 | pubmed:language | eng | lld:pubmed |
| pubmed-article:6308364 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6308364 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:6308364 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6308364 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:6308364 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:6308364 | pubmed:issn | 0302-2137 | lld:pubmed |
| pubmed-article:6308364 | pubmed:author | pubmed-author:SellinL CLC | lld:pubmed |
| pubmed-article:6308364 | pubmed:author | pubmed-author:DasguptaB RBR | lld:pubmed |
| pubmed-article:6308364 | pubmed:author | pubmed-author:KauffmanJ AJA | lld:pubmed |
| pubmed-article:6308364 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:6308364 | pubmed:volume | 61 | lld:pubmed |
| pubmed-article:6308364 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:6308364 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:6308364 | pubmed:pagination | 120-5 | lld:pubmed |
| pubmed-article:6308364 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:6308364 | pubmed:meshHeading | pubmed-meshheading:6308364-... | lld:pubmed |
| pubmed-article:6308364 | pubmed:meshHeading | pubmed-meshheading:6308364-... | lld:pubmed |
| pubmed-article:6308364 | pubmed:meshHeading | pubmed-meshheading:6308364-... | lld:pubmed |
| pubmed-article:6308364 | pubmed:meshHeading | pubmed-meshheading:6308364-... | lld:pubmed |
| pubmed-article:6308364 | pubmed:meshHeading | pubmed-meshheading:6308364-... | lld:pubmed |
| pubmed-article:6308364 | pubmed:meshHeading | pubmed-meshheading:6308364-... | lld:pubmed |
| pubmed-article:6308364 | pubmed:meshHeading | pubmed-meshheading:6308364-... | lld:pubmed |
| pubmed-article:6308364 | pubmed:year | 1983 | lld:pubmed |
| pubmed-article:6308364 | pubmed:articleTitle | Comparison of the effects of botulinum neurotoxin types A and E at the rat neuromuscular junction. | lld:pubmed |
| pubmed-article:6308364 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:6308364 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:6308364 | pubmed:publicationType | Research Support, U.S. Gov't, Non-P.H.S. | lld:pubmed |
| pubmed-article:6308364 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6308364 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6308364 | lld:pubmed |
